Share Print

NF2 Clinical Program at Washington University

Neurofibromatosis 2 (NF2) is a rare genetic condition that leads to the development of multiple tumors of the nervous system. These tumors can result in blindness, deafness, paralysis and other neurologic problems. NF2 can be fatal if untreated when tumors press on the brainstem, spinal cord or brain.

The NF2 Clinical Program at Washington University is the only program in the Midwest specializing in the treatment of NF2. The program – a joint project of Barnes-Jewish Hospital, the Siteman Cancer Center and the Washington University NF Center – has two primary goals:

  • To care for children and adults with NF2 and provide counseling for family members
  • To coordinate research that will lead to the development of new treatments

NF2 Clinical Program co-directors Michael Chicoine, MD, and Jonathan McJunkin, MD, lead a multidisciplinary team that includes a broad spectrum of medical specialists. Team members work together to assess patients and coordinate care. Patients benefit from their experience in caring for a large number of people who are affected by this rare disease.

For more information, click on the links below: